Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329989 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT03329989: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT03329989 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03329989, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.
Interventions
- BIOLOGICAL Collagenase Clostridium Histolyticum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2017-11-17 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03329989
The ClinicalTrials.gov registry entry for NCT03329989 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Collagenase Clostridium Histolyticum is the first listed.
NCT03329989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03329989 about?
NCT03329989 is a clinical study titled "Safety and Effectiveness of EN3835 in the Treatment of EFP in Women". An open-label study of safety and effectiveness of EN3835 in the treatment of cellulite in adult women.
What is the current status of trial NCT03329989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2017-11-17. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT03329989?
The interventions under investigation include: Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT03329989?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.